Stryker
SYK348.0401.20% ( -4.210 )
Q2 FY2026 EarningsQ2 FY26 performance beat consensus across all major metrics: revenue was $6.59B vs. $6.58B expected, and adjusted EPS reached $3.69 vs. $3.49 expected. Growth was broad-based with organic sales up 9.0%, driven by unit volume recovery following a prior cyber incident. Management narrowed full-year organic growth guidance to 8.3%-9.3% and raised the adjusted EPS range to $14.95-$15.10, indicating sustained momentum in MedTech.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Stryker(SYK) predict that the Revenue is 6.589 B (+9.42%), Beat estimate;the EBIT is 1.807 B (+16.96%), Beat estimate;the EPS is 3.3 (+44.1%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
6.59B9.42%
6.58B9.25%
+0.01B0.17%
EBITExceed expectations
1.81B16.96%
1.70B9.98%
+0.11B6.98%
EPSExceed expectations
3.344.10%
2.965329.49%
+0.334714.61%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf